Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Double-blind, randomized, placebo-controlled, escalating multiple-dose, phase I trial to assess the safety, tolerability and pharmacokinetics of SIGA-246 as a single daily dose for 21 days in healthy, non-fasted volunteers.

Next Previous
X
Search
Trial Profile

Double-blind, randomized, placebo-controlled, escalating multiple-dose, phase I trial to assess the safety, tolerability and pharmacokinetics of SIGA-246 as a single daily dose for 21 days in healthy, non-fasted volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tecovirimat (Primary)
  • Indications Orthopoxvirus infections; Smallpox
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 12 Apr 2010 Results published in Antimicrobial Agents and Chemotherapy.
    • 15 Sep 2009 Results presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2009)
    • 06 Dec 2007 Status changed to completed in accordance with SIGA Technologies media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top